Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
809 A bispecific antibody targeting CCR8 & CTLA-4: Potent anti-tumor efficacy with better safety by preferentially eliminating tumor-infiltrating regulatory T cells
Compose a Response to This Article
Other responses
No responses have been published for this article.
